Trial Profile
Phase IIa, Randomised, Controlled, OpenLabel Trial of Rosuvastatin for the Prevention of AminoglycosideInduced Kidney Toxicity in Children with Cystic Fibrosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Aug 2018
Price :
$35
*
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Kidney disorders
- Focus Pharmacodynamics
- Acronyms PROteKT
- 02 Sep 2016 Status changed from recruiting to completed.
- 28 Jan 2016 Accrual to date is 36% according to United Kingdom Clinical Research Network record.
- 03 Dec 2015 Accrual to date is 34% according to United Kingdom Clinical Research Network record.